The estrogen antagonists can inhibit the transcriptional activity of ER, but some of the estrogen-dependent cancer cells can escape this competitive inhibition and activate the ER signaling pathway by growth factors or coactivators, suggesting that the direct targeting on ER protein could be an important therapeutic strategy in those advanced cancer cells [38, 39]. The gene discussed is ESR1; the disease is cancer.